PURE Bioscience and AgroVet Alliance Collaborate on International Supply and License Agreement’
By
CSIMarket.com
EL CAJON, Calif. PURE Bioscience, Inc. (OTCQB: PURE), the developer of the innovative non-toxic silver dihydrogen citrate (SDC) antimicrobial, has entered into a multi-year international supply and license agreement with AgroVet Alliance, FZE (AVA). This strategic partnership aims to expand the distribution and utilization of SDC products across the global animal health and livestock markets.
Jeff Kitchell, Vice President of Operations for PURE, expressed optimism about the agreement, noting that AVA brings extensive experience in the global animal health sector. AVA has been doing business worldwide in animal health and livestock industries for years, Kitchell said, and their expertise will be invaluable as we expand the reach of our SDC products.
The agreement, which involves specific terms and conditions for the purchase and sale of SDC products, is anticipated to enhance the reach and adoption of PURE’s patented antimicrobial solutions. This move aligns with PURE’s broader strategy to leverage innovation and partnerships to capture international market share in the growing field of non-toxic antimicrobial solutions.
In related news, PURE Bioscience reported its financial results for the fiscal third quarter ending April 30, 2024. Net product sales for this quarter were $440,000, reflecting an increase from $406,000 in the same period the previous year. This $34,000 increase was primarily attributed to enhanced sales strategies and growing market demand for SDC products.
The reported financial performance paints a promising picture for PURE, highlighting a steady upward trajectory in sales and a continued commitment to expanding its market footprint. The financial success, coupled with strategic partnerships like the one with AVA, positions PURE Bioscience for significant growth in the coming years.
The international supply and license agreement with AVA is expected to foster broader distribution and increased sales, capitalizing on AVA’s established networks and experience in the animal health and livestock markets. This collaboration could also potentially stimulate further financial growth for PURE, as the market for non-toxic antimicrobial solutions continues to expand.
As PURE Bioscience looks to the future, the combination of strategic partnerships and strong financial performance underscores its potential as a leader in the field of innovative antimicrobial solutions.
Comments